APC anti-mouse CD3ε Antibody

Pricing & Availability
Clone
145-2C11 (See other available formats)
Regulatory Status
RUO
Other Names
CD3ε, T3, CD3
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
145-2C11_APC_021606
C57BL/6 mouse splenocytes were stained with CD3e (clone 145-2C11) APC (filled histogram) or Armenian hamster IgG APC isotype control (open histogram).
  • 145-2C11_APC_021606
    C57BL/6 mouse splenocytes were stained with CD3e (clone 145-2C11) APC (filled histogram) or Armenian hamster IgG APC isotype control (open histogram).
Compare all formats See APC spectral data
Cat # Size Price Save
100311 25 µg ¥7,260
100312 100 µg ¥19,650
Description

CD3ε is a 20 kD transmembrane protein, also known as CD3 or T3. It is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3ε forms a TCR complex by associating with the CD3δ, γ and ζ chains, as well as the TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
H-2Kb-specific mouse cytotoxic T lymphocyte clone BM10-37
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD3ε antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone 145-2C11 is useful for in vitro blocking of target-specific CTL-mediated cell lysis1, as well as T cell activation assays, inducing proliferation and cytokine production1,2,7,12,16. It also induces apoptosis in immature thymocytes32,  and in vivo T cell depletion8-10. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1, immunohistochemical staining14,15 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, Western blotting4, complement-mediated cytotoxicity6, in vitro and in vivo stimulation of T cells1,2,7,12,16, immunofluorescent staining5, and in vivo T cell depletion8-10. The 145-2C11 antibody has been reported to block the binding of 17A2 antibody to CD3 epsilon-specific T cells11. Clone 145-2C11 is not recommended for formalin-fixed paraffin embedded sections. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100314). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100340) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block)
  2. Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ)
  3. Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1.
  4. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB)
  5. Payer E, et al. 1991. J. Immunol. 146:2536. (IF)
  6. Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD)
  7. Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ)
  8. Henrickson M, et al. 1995. Transplantation 60:828. (Deplete)
  9. Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete)
  10. Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete)
  11. Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block)
  12. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ)
  13. Ko SY, et al. 2005. J. Immunol. 175:3309.
  14. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F)
  15. Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F)
  16. Wang W, et al. 2007. J. Immunol. 178:4885. (Activ)
  17. Xiao S, et al. 2007. J. Exp. Med. 204:1691.
  18. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed.
  19. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed
  20. Guo Y, et al. 2008. Blood 112:480. PubMed
  21. Kenna TJ, et al. 2008. Blood 111:2091.
  22. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed
  23. Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed
  24. Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed
  25. de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed
  26. Schulteis RD, et al. 2008. Blood 295:G273. PubMed
  27. Qi Q, et al. 2009. Blood 114:564. PubMed
  28. Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed
  29. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  30. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
  31. Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed
  32. Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)
Product Citations
  1. Wang Q, et al. 2020. Radiat Environ Biophys. 59:89. PubMed
  2. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  3. Chan LC, et al. 2019. J Clin Invest. 129:3324. PubMed
  4. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  5. Barrett N, et al. 2016. Cell Rep. 16: 1039-1054. PubMed
  6. Yamaguchi S, et al. 2021. Eur J Immunol. 51:2306. PubMed
  7. Yang Z, et al. 2022. J Immunother Cancer. 10:. PubMed
  8. Fujimori S, et al. 2022. Elife. 11:. PubMed
  9. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  10. Symeonidou V, et al. 2021. Cell Rep. 37:109900. PubMed
  11. Ajina R, et al. 2019. Oncoimmunology. 8:e1577127. PubMed
  12. Ferrari de Andrade L, et al. 2020. Cancer Immunol Res. 0.867361111. PubMed
  13. Pennock N, et al. 2014. Proc Natl Acad Sci U S A. 111:16472. PubMed
  14. Okamoto M, et al. 2014. J Immunol. 192:2770. PubMed
  15. Nakamura M, et al. 2015. J Immunol. 194:243. PubMed
  16. Yang X, et al. 2020. Blood Sci. 2:89. PubMed
  17. Volpedo G, et al. 2022. NPJ Vaccines. 7:32. PubMed
  18. Agelidis A, et al. 2019. Front Immunol. 10:500. PubMed
  19. Altshuler A, et al. 2021. Cell Stem Cell. 28(7):1248-1261.e8. PubMed
  20. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  21. Roufaiel M, et al. 2016. Nat Immunol. 10.1038/ni.3564. PubMed
  22. Ku M, et al. 2016. Mol Cancer Ther. 15: 1975 - 1987. PubMed
  23. Mukherjee D, et al. 2022. Nat Commun. 13:3747. PubMed
  24. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
  25. Jung BG, et al. 2022. PLoS Pathog. 18:e1010454. PubMed
  26. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  27. Zhou H, et al. 2022. EMBO Rep. 23:e53475. PubMed
  28. Lercher A, et al. 2019. Immunity. 51:1074. PubMed
  29. Gao JL, et al. 2019. JCI Insight. 4:e132140. PubMed
  30. Gorczynski RM, et al. 2017. Immunology. 150:418. PubMed
  31. Wang J, et al. 2018. Front Immunol. 9:371. PubMed
  32. Haugh KA, et al. 2021. eLife. 0.416666666666667. PubMed
  33. Sato K, et al. 2015. PLoS One. 10: 0138291. PubMed
  34. Dane EL, et al. 2022. Nat Mater. 21:710. PubMed
  35. Fujita K, et al. 2019. Proc Natl Acad Sci U S A. 116:14714. PubMed
  36. Wan W, et al. 2015. Cardiovasc Res. 106:478. PubMed
  37. Montel-Hagen A, et al. 2020. Cell Rep. 33:108320. PubMed
  38. Lopez DA, et al. 2022. Cell Rep. 41:111677. PubMed
  39. Leiva M, et al. 2016. Nat Commun. 7:10222. PubMed
  40. Holvoet B, et al. 2015. Stem Cell Reports. 5: 1183-1195. PubMed
  41. Burrack K, et al. 2015. PLoS Pathog. 11: e1005191. PubMed
  42. Dong S, et al. 2021. Nature. 591:117. PubMed
  43. Ghandhi SA, et al. 2022. Sci Rep. 12:14124. PubMed
  44. Codina A, et al. 2019. Cell Syst. 8:136. PubMed
  45. Xu H, et al. 2020. Immunity. 51(4):696-708.e9.. PubMed
  46. Aebischer D, et al. 2014. PLoS One. 9:99297. PubMed
  47. Hum NR, et al. 2022. Front Oncol. 12:928474. PubMed
  48. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  49. Parhi L, et al. 2020. Nat Commun. 2.721527778. PubMed
  50. Mansell E, et al. 2020. Cell Stem Cell. . PubMed
  51. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  52. Ito C, et al. 2015. PLoS One. 10: e0140808. PubMed
  53. Siggs O, et al. 2015. Proc Natl Acad Sci U S A. 112: E5706 - E5714. PubMed
  54. Burrack K, et al. 2015. J Immunol. 194:678. PubMed
  55. Oksenych V, et al. 2021. Biomolecules. 12:. PubMed
  56. Mittal A, et al. 2021. Sci Rep. 11:10731. PubMed
  57. Gu X, et al. 2022. Vaccines (Basel). 10:. PubMed
  58. Liu B, et al. 2022. Mol Med Rep. 26:. PubMed
  59. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  60. Luck H, et al. 2015. Cell Metab. 21 527 . PubMed
  61. Nosho S, et al. 2020. Int J Mol Sci. 21:00. PubMed
  62. Sun Y, et al. 2022. Mol Ther Oncolytics. 25:160. PubMed
  63. Liu Z, et al. 2020. Cell. 178(6):1509-1525.e19.. PubMed
  64. Ghandhi SA, et al. 2019. Sci Rep. 9:19434. PubMed
  65. Xia P et al. 2018. Immunity. 48(4):688-701 . PubMed
  66. Liu S, et al. 2018. Front Immunol. 29:208. PubMed
  67. Uto T, et al. 2016. Nat Commun. 7: 11273. PubMed
  68. Rovira-Clavé X, et al. 2016. J Leukoc Biol. 99: 143 - 152. PubMed
  69. XS R, et al. 2015. Diabetes. 64 90. PubMed
  70. Zhang X, et al. 2021. Mol Cancer Res. 19:1076. PubMed
  71. Li D, et al. 2022. Emerg Microbes Infect. 11:2248. PubMed
  72. Liu Y, et al. 2022. Am J Transl Res. 14:6856. PubMed
  73. Gubin MM, et al. 2018. Cell. 175:1014. PubMed
  74. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  75. Zhang CR, et al. 2022. Blood Cancer Discov. 3:220. PubMed
  76. Zhang Q, et al. 2022. JCI Insight. 7:. PubMed
  77. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  78. Wang W, et al. 2021. J Am Heart Assoc. 10:e019142. PubMed
  79. Berghoff SA, et al. 2021. Nat Neurosci. 24:47. PubMed
  80. Shibuya M, et al. 2021. iScience. 24:103131. PubMed
  81. Liang Q, et al. 2020. Front Microbiol. 11:571847. PubMed
  82. Metidji A et al. 2018. Immunity. 49(2):353-362 . PubMed
  83. Nahrendorf W, et al. 2021. eLife. 10:00. PubMed
  84. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  85. Omatsu Y, et al. 2022. Nat Commun. 13:2654. PubMed
  86. Jing Y, et al. 2021. Front Immunol. 12:651860. PubMed
  87. Celik H, et al. 2018. Cancer Cell. 34:741. PubMed
  88. Kang YH, et al. 2019. Nat Commun. 10:912. PubMed
  89. Castañeda–Zegarra S, et al. 2019. Biomolecules. 0.929166667. PubMed
  90. Casanova-Acebes M, et al. 2018. J Exp Med. 215:2778. PubMed
  91. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  92. Onai N, et al. 2020. Int J Mol Sci. :22. PubMed
  93. Düking T, et al. 2022. Sci Adv. 8:eabo7639. PubMed
  94. Shaikh H, et al. 2021. Front Immunol. 12:689896. PubMed
  95. Bajaña S, et al. 2022. iScience. 25:103732. PubMed
  96. Koide S, et al. 2022. iScience. 25:103603. PubMed
  97. McCauley ME, et al. 2020. Nature. 585(7823):96-101. PubMed
  98. Ulaganathan VK, et al. 2020. Sci Rep. 10:8453. PubMed
  99. Bergquist M, et al. 2014. J Infect. 69:113. PubMed
  100. Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed
  101. Zhou S, et al. 2021. Adv Funct Mater. 31:. PubMed
  102. Sato Y, et al. 2022. Front Mol Biosci. 9:1040237. PubMed
  103. Zhu E, et al. 2014. J Immunol. 192:5599. PubMed
  104. Yang X, et al. 2021. Bioact Mater. 3150:6. PubMed
  105. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  106. Stephens HM, et al. 2022. Methods Mol Biol. 2478:727. PubMed
  107. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  108. Arensman MD, et al. 2020. Oncoimmunology. 9:1800162. PubMed
  109. Parks CA, et al. 2019. Proc Natl Acad Sci U S A. 116:3136. PubMed
  110. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  111. Pelly V, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.4. PubMed
  112. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  113. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  114. Radulovic V, et al. 2020. Cell Reports. 27(10):2826-2836.e5.. PubMed
  115. Liu Z, et al. 2020. STAR Protoc. 1:100029. PubMed
  116. Xu G, et al. 2015. Free Radic Biol Med. 87: 15-25. PubMed
  117. Cruz F, et al. 2016. Stem Cells Trans Med. 5: 488-499. PubMed
  118. Huang X, et al. 2021. Immunity. . PubMed
  119. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  120. Yu YR, et al. 2020. STAR Protocols. 11(3):e0150606. PubMed
  121. Omenetti S, et al. 2019. Immunity. 51:77. PubMed
  122. Tong Y, et al. 2018. EBioMedicine. 39:132. PubMed
  123. Harvey RE et al. 2017. Endocrinology. 158(7):2179-2189 . PubMed
  124. Campisi L, et al. 2016. Nat Immunol. 10.1038/ni.3512. PubMed
RRID
AB_312676 (BioLegend Cat. No. 100311)
AB_312677 (BioLegend Cat. No. 100312)

Antigen Details

Structure
Ig superfamily, forms CD3/TCR complex with CD3δ, γ and ζ subunits and TCR (α/β and γ/δ), 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
TCR signal transduction, T cell activation, antigen recognition
Ligand/Receptor
Peptide antigen/MHC-complex
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules, TCRs
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12501 View all products for this Gene ID
UniProt
View information about CD3epsilon on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account